Page last updated: 2024-11-04

e 4031

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

E 4031: class III anti-arrhythmia agent; structure given in UD [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3185
CHEMBL ID327980
CHEBI ID34732
SCHEMBL ID2168557
MeSH IDM0176392

Synonyms (51)

Synonym
chebi:34732 ,
CHEMBL327980 ,
BRD-K41713976-001-02-0
gtpl2605
e-4031 ,
BIO2_000033
NCGC00025301-01
BIO2_000513
BIO1_000862
BIO1_000373
BIO1_001351
tocris-1808
IDI1_033783
BSPBIO_001313
e4031
NCGC00025301-02
NCGC00025301-03
2-methyl-6-(2-(4-(4-methylsulfonylamino)benzoylpiperidin-1-yl)ethyl)pyridine
methanesulfonamide, n-(4-((1-(2-(6-methyl-2-pyridinyl)ethyl)-4-piperidinyl)carbonyl)phenyl)-
e 4031
n-(4-((1-(2-(6-methyl-2-pyridinyl)ethyl)-4-piperidinyl)carbonyl)phenyl)methanesulfonamide
113558-89-7
KBIO3_000066
KBIO2_000033
KBIO3_000065
KBIO2_002601
KBIOSS_000033
KBIOGR_000033
KBIO2_005169
NCGC00025301-04
HMS1989B15
n-(4-{1-[2-(6-methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide (e-4031)
n-(4-{1-[2-(6-methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide
n-(2-{1-[2-(6-methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide
bdbm50117930
1-(2-(6-methylpyridin-2-yl)ethyl)-4-(4-(methylsulfonamido)benzoyl)piperidinium
(4-{1-[2-(6-methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide
n-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide
HMS1791B15
n-[4-[1-[2-(6-methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide
unii-1l1k8x5df9
1l1k8x5df9 ,
n-[4-[[1-[2-(6-methyl-2-pyridinyl)ethyl]-4-piperidinyl]carbonyl]phenyl]methanesulfonamide dihydrochloride
SCHEMBL2168557
n-[4-[1-[2-(6-methyl-2-pyridyl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide
HMS3402B15
DTXSID00150458
1-[2-(6-methyl-2-pyridyl)ethyl]-4-(4-methylsulfonyl-aminobenzoyl)piperidine
n-[4-[[1-[2-(6-methyl-2-pyridinyl)ethyl]-4-piperidinyl]carbonyl]phenyl]methanesulfonamide dihydrochl
Q5321366
BRD-K41713976-300-01-8

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"We analyzed torsadogenic and pharmacokinetic profile of E-4031 using chronic atrioventricular block dogs."( Analysis of torsadogenic and pharmacokinetic profile of E-4031 in dogs bridging the gap of information between in vitro proarrhythmia assay and clinical observation in human subjects.
Ando, K; Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Naito, AT; Sugiyama, A, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" Compound 5 was shown to have good oral bioavailability and a favorable hemodynamic profile to produce a 3-fold increase of the ventricular fibrillation threshold and to terminate ventricular fibrillation, restoring sinus rhythm in anesthetized dogs."( Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
Bagli, JF; Ellingboe, JW; Kitzen, JM; Moubarak, IF; Nguyen, TT; Parsons, RW; Spinelli, W; Von Engen, D; Winkley, MW, 1992
)
0.28
"Here we show a curcumin encapsulated lipopolymeric hybrid nanoparticle formulation which could protect against QT prolongation and also render increased bioavailability and stability thereby overcoming the limitations associated with curcumin."( Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation.
Helson, L; Mukerjee, A; Ranjan, AP; Vishwanatha, JK, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" Agents were compared over dosage ranges that produced maximal increases in QTc interval and monophasic action potential duration (MAPD)."( Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G, 1993
)
0.29
" Hypothermia shifted the dose-response curves to the right for the negative chronotropic and inotropic effects of verapamil and for the negative chronotropic and positive inotropic effects of zatebradine, but not for the negative chronotropic and positive inotropic effects of E-4031."( Effects of low temperature on the chronotropic and inotropic responses to zatebradine, E-4031 and verapamil in isolated perfused dog atria.
Chiba, S; Furukawa, Y; Hoyano, Y; Kasama, M; Oguchi, T, 1998
)
0.3
" Notably, cells aligned on the biomimetic platform responded detectably down to a dosage of 3 nM E-4031, which is lower than the IC50 in the hERG channel assay."( Integrated platform for functional monitoring of biomimetic heart sheets derived from human pluripotent stem cells.
Chen, A; Fowlkes, C; Grosberg, A; Khine, M; Lee, E; Santiago, K; Tu, R, 2014
)
0.4
" Remarkably, both contractility (impedance) and extracellular field potentials (EFPs) could be detected from the actively beating spheroids over long durations and after automated dosing with pharmacological agents."( A Scalable Approach Reveals Functional Responses of iPSC Cardiomyocyte 3D Spheroids.
Burnham, MP; Fertig, N; Haddrick, M; Harvey, R; Sargeant, R, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency35.48130.141337.9142100.0000AID1490
regulator of G-protein signaling 4Homo sapiens (human)Potency18.84590.531815.435837.6858AID504845
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency1.99530.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency7.94330.00255.840031.6228AID899
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency6.30960.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency5.62340.251215.843239.8107AID504327
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)0.03810.00091.901410.0000AID1301039; AID1301347; AID1471791; AID1516989; AID1561773; AID1595980; AID1596628; AID161281; AID1772929; AID1861995; AID240820; AID243151; AID392051; AID408340; AID420668; AID576612; AID82355
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)EC50 (µMol)0.02500.00192.67568.0000AID1244290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (90)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID59096Effect on atrial conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 0.1 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID63288Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.10 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56672repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.01 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56695Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 300 ms, repolarization time to -60 mV1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID217775Inhibition of hERG Voltage-gated potassium channel subunit Kv11.1 expressed in COS7 cells by electrophysiological whole cell assay2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
AID62965Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1244290Inhibition of human ERG assessed as reduction of tail current2015European journal of medicinal chemistry, Aug-28, Volume: 1014-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model.
AID1301347Inhibition of human ERG expressed in cell membranes after 4 hrs by fluorescence polarization assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.
AID59247Effect on heart rate, after intravenous administration in open-chest anesthetized dogs at dose of 0.1 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID1874016Inhibition of hERG at 10 uM incubated for 2 hrs by fluorescence polarization based assay relative to control2022Bioorganic & medicinal chemistry, 08-15, Volume: 68Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation.
AID22627Maximum rate of depolarization of the upstroke of the action potential1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID59218Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID56693Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 1000 ms, repolarization time to -60 mV, at a concentration of 0.3 uM1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID56507Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID59261Effect on ventricular conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 0.1 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID1516989Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID59249Effect on heart rate, after intravenous administration in open-chest anesthetized dogs at dose of 1.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID1301038Inhibition of human ERG expressed in CHOK1 cells assessed as inhibition of tail current at 10 uM after 5 mins by automated whole-cell patch clamp assay relative to control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID56680Repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.01 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID63285Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.01 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID71923Dose required to produce 20% increase in effective refractory period in male ferret.2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and class III type antiarrhythmic activity of 4-aroyl (and aryl)-l-aralkylpiperazines.
AID1596628Inhibition of fluorescently labeled tracer binding to human ERG by competitive binding assay2019European journal of medicinal chemistry, Aug-01, Volume: 175Ligand retargeting by binding site analogy.
AID1772929Inhibition of human ERG incubated for 3 hrs by competitive fluorescence tracer binding based assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID59267Effect on ventricular effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 0.1 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID62967Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1861995Inhibition of hERG measured by fluorescence polarization assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID56506Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID59243Effect on atrial effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 1.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID59147Compound was evaluated for the intravenous dose required to prolong relative refractory period (RRP) 20 ms above baseline in chloralose anesthetized dogs using a paired pacing protocol1992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
4-Oxospiro[benzopyran-2,4'-piperidines] as class III antiarrhythmic agents. Pharmacological studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-on e (L-691,121).
AID59269Effect on ventricular effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 1.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID75648Effective refractory period of contractile response in isolated guinea-pig papillary muscles at 1 Hz and 1 uM.1999Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1
Synthesis and biological activity of KCB-328 and its analogues: novel class III antiarrhythmic agents with little reverse frequency dependence.
AID56698Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 300 ms, repolarization time to -60 mV, at a concentration of 0.3 uM1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID71928Compound was evaluated for the molar concentration required to prolong effective refractory period (ERP) 25% above baseline in ferret isolated right ventricular papillary muscles using a paired pacing protocol1992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
4-Oxospiro[benzopyran-2,4'-piperidines] as class III antiarrhythmic agents. Pharmacological studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-on e (L-691,121).
AID62937Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID232589Ratio of ERPc prolongation was measured as percent change at 3 Hz/1 Hz1999Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1
Synthesis and biological activity of KCB-328 and its analogues: novel class III antiarrhythmic agents with little reverse frequency dependence.
AID59253Effect on mean arterial pressure, after intravenous administration in open-chest anesthetized dogs at dose of 0.1 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID72554Peak isometric tension during the basic stimulus trains (S1) during control and compound induced tension, expressed as percent control.2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and class III type antiarrhythmic activity of 4-aroyl (and aryl)-l-aralkylpiperazines.
AID63284Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.01 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56683Repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.10 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56505Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID62936Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID59098Effect on atrial conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 1.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID62935Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID59102Effect on atrial effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 0.1 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID63286Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.03 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56673repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.03 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56529Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID75649Effective refractory period of contractile response in isolated guinea-pig papillary muscles at 3 Hz and 1 uM.1999Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1
Synthesis and biological activity of KCB-328 and its analogues: novel class III antiarrhythmic agents with little reverse frequency dependence.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID9924Maximum rate of depolarization of the upstroke of the action potential1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID1207647Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1595980Inhibition of tracer Red binding to human ERG expressed in membranes after 3 hrs by fluorescence polarization assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Novel Tetrahydroquinazolinamines as Selective Histamine 3 Receptor Antagonists for the Treatment of Obesity.
AID62966Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID59263Effect on ventricular conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 1.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID56674repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.10 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56681Repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.03 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID56528Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID59219Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1561773Inhibition of human ERG expressed in HEK293 cells by patch clamp assay2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology.
AID58463Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56689Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 1000 ms, repolarization time to -60 mV1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID63287Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.03 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1471791Inhibition of human ERG by fluorescently labeled tracer binding method2017Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.
AID1301036Inhibition of human ERG expressed in CHOK1 cells assessed as inhibition of tail current at 0.1 uM after 5 mins by automated whole-cell patch clamp assay relative to control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1458666Inhibition of human ERG expressed in CHO cells at 1 x 10'-6 M by patch clamp method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1301037Inhibition of human ERG expressed in CHOK1 cells assessed as inhibition of tail current at 1 uM after 5 mins by automated whole-cell patch clamp assay relative to control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID82355K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID59217Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID63289Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.10 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID59255Effect on mean arterial pressure, after intravenous administration in open-chest anesthetized dogs at dose of 1.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID58464Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID392051Inhibition of human ERG channel in HEK293 cells by voltage-clamp method2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation.
AID56527Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID58465Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1301039Inhibition of human ERG expressed in CHOK1 cells assessed as inhibition of tail current after 5 mins by automated whole-cell patch clamp assay2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1346751Human Kv11.1 (Voltage-gated potassium channels)1998Biophysical journal, Jan, Volume: 74, Issue:1
Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature.
AID1346735Rat Kv11.1 (Voltage-gated potassium channels)1997The Journal of neuroscience : the official journal of the Society for Neuroscience, Dec-15, Volume: 17, Issue:24
Identification of two nervous system-specific members of the erg potassium channel gene family.
AID1346732Human Kv10.1 (Voltage-gated potassium channels)2003British journal of pharmacology, Jan, Volume: 138, Issue:1
Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241.
AID1346727Rat Kv11.3 (Voltage-gated potassium channels)1997The Journal of neuroscience : the official journal of the Society for Neuroscience, Dec-15, Volume: 17, Issue:24
Identification of two nervous system-specific members of the erg potassium channel gene family.
AID1346761Rat Kv11.2 (Voltage-gated potassium channels)1997The Journal of neuroscience : the official journal of the Society for Neuroscience, Dec-15, Volume: 17, Issue:24
Identification of two nervous system-specific members of the erg potassium channel gene family.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (341)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's139 (40.76)18.2507
2000's106 (31.09)29.6817
2010's83 (24.34)24.3611
2020's13 (3.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.49 (24.57)
Research Supply Index5.88 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index43.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.28%)5.53%
Reviews4 (1.12%)6.00%
Case Studies1 (0.28%)4.05%
Observational0 (0.00%)0.25%
Other350 (98.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]